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Dementia with Lewy bodies
Parkinson's diseaseations have identiﬁed major hallmarks of chronic neurodegenerative disease.
These include protein aggregates called Lewy bodies in dementia with Lewy bodies and Parkinson's disease.
Mutations in the α-synuclein gene have been found in familial disease and this has led to intense focused
research in vitro and in transgenic animals to mimic and understand Parkinson's disease. A decade of
transgenesis has lead to overexpression of wild type and mutated α-synuclein, but without faithful
reproduction of human neuropathology and movement disorder. In particular, widespread regional neuronal
cell death in the substantia nigra associated with human disease has not been described. The intraneuronal
protein aggregates (inclusions) in all of the human chronic neurodegenerative diseases contain ubiquitylated
proteins. There could be several reasons for the accumulation of ubiquitylated proteins, including
malfunction of the ubiquitin proteasome system (UPS). This hypothesis has been genetically tested in mice
by conditional deletion of a proteasomal regulatory ATPase gene. The consequences of gene ablation in the
forebrain include extensive neuronal death and the production of Lewy-like bodies containing ubiquitylated
proteins as in dementia with Lewy bodies. Gene deletion in catecholaminergic neurons, including in the
substantia nigra, recapitulates the neuropathology of Parkinson's disease.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionWalk in the street of any city in the world and you will notice more
and more ageing people. Demographic predictions indicate that the
ageing population is set to grow further and further, with centenarians
becoming commonplace in many countries of the world [1]. The
increasing numbers of the ageing population can be attributed to the
control of childhood and adult infectious disease, public health
improvements and good nutrition. This creates new problems for
society, ranging from paying pensions for ever increasing periods to
the construction of residential or nursing homes for the elderly. The
only robust predictable correlation of dementing illness is age.
The brain has been described as a multi-organ system. Irrespective
of this overarching notion, the brain shows profound structural and
functional complexity as might be expected to control the behavioral
and physiological activities of the body. There are several neuro-
transmitters that via different neuronal receptors regulate electrical
activity in different parts of the brain. The neurotransmitters include
glutamate, acetylcholine, serotonin, γ-amino butyric acid and
dopamine.
Deﬁcits in dopamine were detected many years ago in regions of
the brain associated with Parkinson's disease [2,3]. This led to the use
of levo-dopa and dopa decarboxylase inhibitors to treat Parkinson'sayer).
l rights reserved.disease. The use of these drugs and others to treat Parkinson's disease
does not prevent neuronal death: disease progression is irreversible.
The ﬁndings in Parkinson's disease led to the search for neurochemical
deﬁcits in the brain in other neurodegenerative diseases. Declining
acetylcholine was found in certain parts of the brain in Alzheimer-
related disorders, including Alzheimer's disease and dementia with
Lewy bodies [4]. In turn, these observations led to the development of
acetyl cholinesterase inhibitors to treat the symptoms of these
diseases.
In order to try and gain an overall understanding of the molecular
changes in chronic neurodegenerative disease it is necessary to
remember that in the ageing brain there are a variety of neuropatho-
logical problems that are associated with cognitive decline and
movement disorders, in addition to neuronal death. These pathologies
may appear as hallmarks that characterise a speciﬁc disease, e.g.
proteinaceous aggregates such as Lewy bodies in neurons in the
substantia nigra in Parkinson's disease or neuroﬁbrillary tangles in
neurons in Alzheimer's disease. However, it is increasingly clear that
these pathologies can be present together in the brains of many
patients presenting with cognitive decline [5]. If drugs are to be
developed to target fundamental defects in cellular physiology, it will
be important to have diagnostic methods to determine which are
present. The historical diagnosis and division of the major chronic
neurodegenerative diseases into entities such as Parkinson's disease
and Alzheimer's disease could be unhelpful because of the over-
lapping pathologies found in many patients. It is possibly more useful
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bodies and neuronal loss together with extensive gliosis (glial cells
proliferate in association with advancing pathology in the brain).
Emphasis must be placed on the key, sometimes overlooked, major
pathological ﬁnding in the ageing brain, neuronal death. This
predominant event in the brain in Alzheimer's disease and Parkinson's
disease has so-far not been recapitulated in transgenic models of
disease. Animal models have been generated to over-express normal
or mutated versions of the proteins that accumulate in aggregates in
the diseases without extensive neurodegeneration [6]. There is much
in vitro experimental evidence that fragments of the Alzheimer
precursor protein can cause cell death in neuronal cell lines or primary
neurons [7], but this does not generally occur in transgenic animals
expressing large quantities of these so-called amyloidogenic proteins.
Real understanding of chronic neurodegeneration will only come
about when there is experimental insight into the mechanisms of
neuronal cell death together with intraneuronal inclusion body and
extraneuronal amyloid formation.
The Lewy bodies that are found in surviving neurons in the
substantia nigra in Parkinson's disease and cortex in dementia with
Lewy bodies contain α-synuclein and ubiquitylated proteins. Putative
precursors of Lewy bodies (pale bodies) also contain mitochondria.
The diseases are characterised by extensive neuronal cell death. How
can this be explained? Furthermore for progress in understanding and
treating disease can these neuropathological features be recapitulated
in animal models?
2. The ubiquitin proteasome system
Protein ubiquitylation/deubiquitylation has moved from the
periphery to centre stage in cell physiology, cooperating and
competing with protein phosphorylation/dephosphorylation in the
control of cellular activities. Ubiquitin was initially intensely studied
as a tag for the degradation of target proteins by the 26S proteasomeFig. 1. The 26S proteasome: showing the 20S catalytic core (α7β7β7α7) and one of the
two 19S regulator complexes bound to a polyubiquitylated target protein. Another 19S
regulator complex can be found at the other end of the 20S core.[8]. Regulated protein degradation is a major force in the cell to
control the concentration of key regulatory proteins like transcription
factors. Abnormal degradation of such molecules plays an important
role in cancer [9]. However, protein ubiquitylation has many other
roles in eukaryotic cells [10]. Proteins are monophosphorylated on
serines, threonines and tyrosines to achieve regulatory diversity in
the cell. Proteins can be monoubiquitylated on single lysine residues,
polyubiquitylated on single or multiple lysines, e.g. p53 [11] or
multiubiquitylated on different lysines to achieve regulatory diversity
in the cell [12].
The 26S proteasome consists of a cylindrical multi-subunit 20S
catalytic core (α7β7β7α7) together with two 19S end caps. Each 19S
particle consists of a nine subunit base and a lid containing multiple
non-identical subunits, involved in functions including the recogni-
tion of polyubiquitylated proteins destined for degradation [13]. The
base contains six related, but non-identical and non-redundant
ATPases of the AAA superfamily of ATPases (ATPases of Alternative
Activities). The putative heterohexameric ring of ATPases is a protein
unfolding machine to feed string-like polypeptides into the catalytic
core of the 26S proteasome [14] after deubiquitylation by proteasomal
deubiquitylating enzymes. Two of the non-ATPases in the base appear
to form a central “stub” composed of rpn2 attached to the 20S
proteolytic core with rpn1 sitting on top of rpn2 [15]. The rpn2 protein
interacts with the N-terminus of rpn13, which is a receptor for
ubiquitylated proteins [16]. The C-terminus of rpn13 is attached to
deubiquitylating enzyme Uch37. It is tempting to speculate that the
“stub” acts as a central hub separated by an annulus from the putative
hexameric ATPases. Target proteins could be unfolded in the central
annulus between the ATPase ring and the central “stub” following
deubiquitylation to produce the string-like polypeptides for insertion
into the 20S catalytic core. Such mechanical coupling of ATPase
activity to protein movement is reminiscent of the rotary biochemical
mechanism of the mitochondrial F1-ATPase [17] (Fig. 1).
Other forms of proteasomes also exist in the cell [18] and it is
increasingly seen that proteasomes have many roles. For example, in
the regulation of transcription where 26S proteasomes, 20S protea-
somes, 19S particles and sub-particles, and ATPases independent of
20S (APIS) [19] are associated with transcriptional complexes for
different genes [20–22].
The ubiquitin proteasome system (UPS) has many important roles
in neuronal development and homeostasis [23,24]. Synaptogenesis
and synaptic plasticity are, in part, regulated by the UPS [25]. Synaptic
functions and electrical activity are regulated by the combined
processes of protein synthesis and protein degradation by the UPS
[23,26]. In turn, normal behaviors and memory [27] are regulated by
the UPS. The functions and stability of neurotransmitter receptors and
the organization of the post-synaptic density are controlled by the
UPS [28]. Protein synthesis and degradation are not conﬁned to the
neuronal cell body but also occur in synapses to control synaptic
morphology and electrical activity.
Protein degradation in all cells is not mediated by one mechanism.
In addition to the UPS, which degrades cytosolic and nuclear proteins,
there is the autophagic and endosome-lysosome system. Interestingly,
autophagy is controlled by an enzyme cascade involving ubiquitons,
cousins of ubiquitin [10]. The endosome-lysosome system is likewise
regulated by ubiquitin, through the ubiquitylation of the tails of
ligand-bound receptors to ensure internalization along with other
post-translation modiﬁcations, e.g. phosphorylation [10,29,30]. Pro-
tein ubiquitylation is also needed for the delivery of cargo into
multivesicular bodies — via the so-called ESCRT complexes (endoso-
mal sorting complexes required for transport) for fusion with
lysosomes and destruction of the contents of the multivesicular
bodies [31]. It is interesting and perhaps evolutionarily predictable,
that ubiquitons should have been used to control all the known
protein degradation systems in the cell (except perhaps the
mitochondrial degradation systems?).
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particular importance in the nervous system because, in general, adult
neurons do not divide and therefore protein elimination from neurons
assumes particular importance in situations where proteins become
damaged, e.g. oxidized or undergo structural changes such as
conformational changes as in chronic neurodegenerative disease.
The ﬁrst indications of the activity of the UPS in neurons in disease
were the detection by ubiquitin immunohistochemistry of ubiquity-
lated proteins in protein inclusions in all the major chronic neurode-
generative diseases [reviewed in [32]]. Furthermore, the detection of
cortical Lewy bodies by ubiquitin immunocytochemistry facilitated the
identiﬁcation and further clinical deﬁnition of dementia with Lewy
bodies as a chronic neurodegenerative disease [33–36]. As is usual in
biomedical science, the difﬁculty has been to explainwhy ubiquitylated
proteins accumulate in protein aggregates in all the different chronic
neurodegenerative diseases. There could be several explanations for
accumulation of ubiquitylated proteins in inclusions, including mal-
function or overwhelming of the 26S proteasome or ubiquitylation of
proteins as part of a signaling pathway for cell survival or death.
Ubiquitylated proteins may accumulate in inclusions as part of a
mechanism, possibly related to the “aggresome” response, to protect
neurons from cell death. Alternatively, as some believe, protein
ubiquitylation may be a late event in inclusion biogenesis and perhaps
an epiphenomenon in relation to disease progression and cell death.
The signaling pathways (neuronal and/or glial) involved in
aggresome formation and neuronal survival or cell death are currently
incompletely characterised.
Ubiquitylation has been shown to be part of a signaling pathway in
afﬂicted neurons. Protein aggregate formation in tissue culture cells
(not caused by disease-associated aggregate-prone proteins) causes
transient expression of theMEK5 gene. The MEK5 kinase has only one
known downstream substrate ERK5. This pathway has important
developmental roles, e.g. in the heart [37], thymocytes [38] and during
angiogenesis [39], but also functions in neuronal survival mechanisms
in response to retrogradely transported nerve growth factor [40] and
in response to neuronal oxidative damage [37]. Immunohistochem-
istry with antibodies to MEK5 and ERK5 showed that both
neuroﬁbrillary tangles and Lewy bodies contain MEK5 and the
afﬂicted perikarya are enriched in ERK5 [41]. These ﬁndings provide
evidence for a potential generic survival pathway in response to
protein aggregates, which appears to take place in neurons containing
the inclusions associated with chronic neurodegenerative disease.
Neuroﬁbrillary tangles and Lewy bodies contain the p62 protein,
which is also involved in signaling in the cell, e.g. in the NFKB system
[42 43]. A direct molecular connection between the presence of
ubiquitylated proteins in inclusions and MEK5 can be made through
the p62. The p62 protein has a C-terminal UBA domain that binds to
ubiquitylated proteins for delivery to the 26S proteasome [44]. The
p62 protein also belongs to a small family of proteins that have N-
terminal PB1 domains that can either self-associate to give oligomeric
signaling platforms or bind to other proteins with PB1 domains to
form linked functional complexes in the cell. The MEK5 kinase has an
N-terminal PB1 domain and binds to p62 [45,46].Therefore, ubiqui-
tylation of proteins will cause binding of p62 and in turn MEK5 that
will phosphorylate ERK5 and activate transcription factors. If this then
causes the expression of cell-survival genes in neurons in the human
brain containing neuroﬁbrillary tangles or Lewy bodies an adaptive
response pathway can be proposed. The MEK5 kinase is also
associated with inclusions in other neurodegenerative diseases;
including frontotemporal dementia and progressive supranuclear
palsy (Lowe and Mayer, unpublished). The p62 protein also has a
key role in autophagy, which is also another potential reason
explaining why p62 is in inclusions in chronic neurodegenerative
disease [47,48].
The connection between the UPS and chronic neurodegenerative
diseases was enhanced by the identiﬁcation of the parkin gene whichis mutated in autosomal recessive juvenile onset of Parkinson's
disease. Parkin is an ubiquitin protein ligase [49]. Normal parkin
accumulates in Lewy bodies in the disease [50]. Interestingly, Lewy
bodies do not formwhen parkin is mutated suggesting that the ligase
has a direct role in Lewy body formation [49]. The connection between
the UPS and chronic neurodegenerative disease is also shown by
mutations of a deubiquitylating enzyme UCHL-1 (PGP9.5) in a small
group of patients with familial Parkinson's disease [51]. It is possible
that parkin and UCHL-1 are important upstream players in synuclei-
nopathies. Genome-wide linkage analysis of a pedigree of parkinso-
nian-pyramidal syndrome has shown linkage to chromosome 22 and
sequencing of candidate genes showed disease-associated homozy-
gous variation in an F-box protein, which is a substrate-receptor for a
ubiquitin protein ligase [52]. Given the importance of the UPS for
neuronal development and homeostasis, it is not surprising that
mutations in genes for proteins of the UPS cause chronic neurode-
generative disease. Neurological abnormalities are seen in a variety of
transgenic mouse models with deﬁcits in the UPS [53].
Whereas genetics identiﬁes mutant proteins associated with
disease it is more difﬁcult to prove the role of a pathway in disease.
Some indirect evidence for malfunction of the proteasome in chronic
neurodegenerative disease comes from the observation that protea-
somal catalytic activity is reduced in the substantia nigra in
Parkinson's disease [54]. Similarly, the ubiquitin proteasome system
appears impaired in the ageing brain [55] and particularly so in
Huntington's disease [56], Creutzfeld–Jakob disease, Alzheimer's
disease [57,58], as well as in brain ischaemia [59,60].
The systemic administration of proteasomal inhibitors has been
reported to cause Parkinson-like neuropathological changes, includ-
ing the formation of Lewy-like inclusions in rodents [61]. However,
these observations are controversial with some laboratories being
unable to reproduce the original ﬁndings [62–65]. Interestingly, α-
synuclein protoﬁlaments, but not monomers or dimers, inhibit the
catalytic activity of the 26S proteasome in vitro [66].
In summary, the neuropathological insight and conclusions drawn
from theseﬁndings pertaining to chronic neurodegenerative disease are;
• In neurodegenerative disease neuronal inclusions contain different
proteins
• Inclusions have a primary role in disease
• Overexpression of proteins found in inclusions in mouse models
may mimic disease (or overexpression of extracellular amyloid)
• The majority of intraneuronal inclusions contain ubiquitylated
proteins
• Genetic insight into human neurodegenerative disease supports
involvement of the UPS
• Impairment of the UPS may cause disease and
• The role of the UPS is uncertain, e.g. is the UPS the primary
response to protein aggregation (c.f. autophagy) and is the system
cytoprotective?
There is clearly a need for the genetic proof or otherwise of the
importance of the UPS in the chronic neurodegenerative diseases.
3. Proteasomal gene targeting
A decade of transgenesis in which disease-associated proteins are
over-expressed singly or together in the brain has produced some, but
not all features of human disease: neurodegeneration has been
conspicuously absent in models of Alzheimer's disease [6] and
Parkinson's disease [67]. For example, mice overexpressing mutant
human α-synuclein in the brain show loss of motor neurons in the
spinal cord, but not neuronal loss in the brain [68]. These ﬁndings have
been rationalized by the notion that mice are short lived animals
(longevity of 2–3 years), whereas human disease occurs much later in
life. In idiopathic cases, usually in the ﬁfth to eighth decades. However,
plaques can form remarkably rapidly, within 24 h, in a transgenic
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view is that mice are not men and may be of limited value in seeking
the molecular key to chronic neurodegenerative disease [6,67].
The alternative to transgenic over-expression of disease-related
proteins is gene targeting, where candidate genes are deleted to see if
neurodegeneration ensues. The targeted deletion of two autophagy-
related genes in the brain results in neurodegeneration, but not the
neuropathological features of human disease [70,71]. Clearly, as
expected, genes for proteins involved in autophagic protein degrada-
tion are important for neuronal homeostasis and when deleted result
in neurodegenerative disease. Such models can be further reﬁned by
conditional gene targeting, and gene ablation in speciﬁc regions of the
brain to reﬂect selective vulnerability seen in neurological illnesses.
There is, of course, the dilemma of the choice of the appropriate gene
for deletion.
Based on the ﬁnding of abundant ubiquitylated proteins in
inclusions in all the human chronic neurodegenerative diseases, it
was logical to hypothesise that conditional deletion of a proteasomal
protein in the brain may recapitulate the neuropathological and
behavioral abnormalities of different human neurodegenerative
diseases. In addition, it is wiser to delete a 19S regulator gene than a
20S core gene, in order to be able to examine a corollary hypothesis
that 20S catalytic activity may be sufﬁcient to prevent neurodegen-
eration. In vitro, 20S proteasomes have been shown to degrade α-
synuclein and tau [72,73]. Affecting a 19S proteasomal gene would
demonstrate if ubiquitylated proteins could accumulate in the cell and
be followed by recapitulation of any of the neuronal inclusions found
in human disease. The six proteasomal ATPases are non-redundant
[74] and putative hexameric ring formation will not occur in neurons
lacking an individual ATPase. An attractive candidate gene is the
Psmc1 ATPase gene (S4/rpt2), since studies in yeast and in vitro show
that this ATPase has a central role in connecting protein unfolding to
the proteolytic activity of the 20S proteasome core [75,76]. Condi-
tional targeted deletion of an ATPase gene in mouse brain might be
expected to recapitulate the elusive neuronal cell death, which is so
prevalent in human chronic neurodegenerative disease and, in the
process, produce inclusions characteristic of human disease.
A formidable and technically successful method of gene deletion
involves the use of the Cre/loxP system [77]. In this approach, the gene
of interest is modiﬁed by the insertion of intronic loxP sequences, such
that in the presence of Cre recombinase, the loxP ﬂanked region is
deleted. Once mice carrying the “ﬂoxed” target gene have been
established these are mated with appropriate “Cre-deletor” mice to
cause spatiotemporal ablation of the gene of interest. In theory, the
gene of interest can be deleted in any cell type in the body of the
“ﬂoxed” mice with an appropriate cell-speciﬁc Cre recombinase.
Deletor strains of mice are available so that ablation of the Psmc1
gene will only occur in catecholaminergic neurons [78], including
dopaminergic neurons of the substantia nigra, or in the forebrain
(cortex, hippocampus, striatum and amygdala) [79,80]. Deletion of the
gene in the substantia nigra may cause the neuropathology of
Parkinson's disease, while deletion of the gene in the forebrain may
cause an Alzheimer-related disorder e.g. dementia with Lewy bodies.
This experimental approach has been successful [81]. Crosses of
“ﬂoxed” Psmc1 mice with tyrosine hydroxylase (TH)-driven Cre
recombinase mice leads to the death of nigrostriatal neurons and the
appearance of Lewy-like bodies in the substantia nigra, and pathog-
nomic characteristics of Parkinson's disease. Nissl staining shows loss
of neuronal RNA-containing rough endoplasmic reticulum in surviving
neurons. Statistical evidence for enlarged neuronal nuclei (nucleome-
galy) perhaps suggests that S4-depleted neurons instigate the cell
cycle as part of the neuronal death process (Bedford and Mayer,
unpublished). This has been demonstrated in the nigra in Parkinson's
disease [82] and in models of neuronal loss in the brain [83].
Using a calcium calmodulin-dependent protein kinase IIα (Cam-
KIIα)-expressing Cre recombinase mouse results in Psmc1 inactiva-tion in forebrain regions. Neuronal cell death and Lewy-like bodies
characteristic of dementia with Lewy bodies are found in the
forebrain, together with some behavioral abnormalities of the disease
[81]. The neuropathology is relatively rapid in these mouse models,
within 12 weeks. Chronic neurodegeneration may occur in old people
but can be reproduced in a matter of weeks in these models [81].
The sequence of events in the “Lewy mouse” begins with the
accumulation of ubiquitylated proteins in neurons following 26S
proteasomal depletion. Selective 26S depletion, with retention of 20S
activity, was conﬁrmed by glycerol gradient analyses. The appearance
of α-synuclein, ubiquitin and p62 positive Lewy-like inclusions and
progressive neurodegeneration and gliosis follow rapidly. Neuronal
death is indicative of apoptotic mechanisms. Ablation of the ATPase
gene in catecholaminergic neurons occurs throughout the autonomic
nervous system and in the neuroendocrine adrenal medulla, resulting
in the premature death of these animals. The neurodegeneration in
the nigrostriatal pathway is accompanied by a corresponding loss of
catecholamines, including dopamine in appropriate regions of the
brain, but not indolamines. Following forebrain-speciﬁc deletion of
Psmc1, comprehensive analyses indicate progressive behavioral and
memory deﬁcits, including a decline in visuospatial memory functions
that may mimic those seen in dementia with Lewy bodies. Details of
these behavioural abnormalities can be found in the supplementary
information of Bedford et al. These neuropathological changes and
behavioral abnormalities occur after deletion of 26S proteasomes
without any evidence for the accumulation of amyloid plaques or
neuroﬁbrillary tangles. Therefore, extensive neuronal cell death and
Lewy-like body deposition can occur in the brain in the absence of the
neuropathological hallmarks of Alzheimer's disease. The immunohis-
tochemical andmorphological features of neurons in 26S proteasome-
depleted mice are indicative of an “aggresomal” pathway of
neurodegeneration, involving α-synuclein, protein ubiquitylation,
p62 and other proteins together as seen in human disease.
Additionally, mitochondria are a prominent feature of the inclusions
in surviving neurons.
The occurrence of α-synuclein in Lewy-like bodies after 26S
proteasome deletion is interesting and suggests that α-synuclein is
not only involved in phospholipid and synaptic vesicle function [84],
but may also have a primary role in Lewy body formation. This would
explain why α-synuclein is present in Lewy bodies. An accepted
notion [85] is that the aggregate-prone α-synuclein (and mutant
forms) is deposited in Lewy bodies deliberately as a sequestration
pathway to remove the protein from the cytoplasm (in addition to
being degraded by the UPS and autophagy). However, ifα-synuclein is
necessary for Lewy body formation and the Lewy body is a speciﬁc
cytoprotective response, then this gives a primary and functional
reason for the incorporation of α-synuclein (and mutant forms?) into
Lewy bodies.
Ultrastructural observations in the “Lewy mice” show that the
perinuclear Lewy-like bodies are built around a core of mitochondria,
surrounded by ﬁlamentous material with a periphery of membranes
and autophagolysomes. This picture is the same as in Epstein–Barr
virus transformed lymphoblastoid cells expressing a small number of
viral proteins including the latent membrane protein [86]. In the
mouse, inclusions containing mitochondria may be the equivalent of
“pale bodies” seen in human disease, which containmitochondria and
may be an early form of Lewy body [81, 87]. In themousemodels, early
neuronal death will prevent the formation of mature Lewy bodies,
containing predominately aggregated ﬁlamentous α-synuclein [81].
4. The 26S proteasome-depleted models for the understanding
and treatment of Parkinson's disease and dementia with
Lewy bodies
The outcomes of conditional Psmc1 gene deletion in the
nigrostriatal pathway and forebrain support the hypothesis that the
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Depletion of 26S proteasomes will cause chronic neurodegenerative
disease, resembling both Parkinson's disease and dementia with Lewy
bodies [81]. Additionally, residual 20S proteasomes are insufﬁcient for
neuronal survival. The ﬁndings have considerable implications for
human diseases, which are generally thought of as diseases of old-age
with neuropathological changes occurring over periods of years.
There is increasing evidence that the pathologies associated with
dementia with Lewy bodies, Parkinson's disease and Alzheimer's
disease co-exist in the ageing brain to varying degrees and at the same
time [5]. For example, most patients with Parkinson's disease
eventually become demented with extensive cortical and brain stem
Lewy bodies [88]. Patients with Alzheimer's disease have Lewy body
pathology, with as many as 60% having Lewy bodies in the amygdala
[89]. Clinically, the diseases are seen to be heterogeneous, a mixture of
pathologies, neurochemical deﬁcits and cognitive decline, making
treatment through neurochemical replacement or receptor agonists
difﬁcult. There are only small “windows of opportunity” for treatment
with existing drugs and complex responses depending on the
pathological nature and extent of disease in the brains of individual
patients [5]. Hence the need for new approaches that will come from
studies on models including the “Lewy” mice. What is already clear
from these mice is that neuronal death can be triggered by depletion
of 26S proteasomes in the absence of neuroﬁbrillary tangles or plaque
amyloid. Yet, the opposite is not true in the transgenic overexpressingFig. 2. A dysfunctional 26S proteasome-dependent pathway for neurodegeneration. The pat
coupled with attempts to eliminate aggregate-prone proteins and inclusion body formation
death by a mechanism based on expression of apoptotic genes and mitochondrial apoptosomodels, abundant amyloid and/or tangles or α-synuclein deposits do
not give rise to rapid or extensive neuronal death in the brain [6,68].
One scenario is that neuroﬁbrillary tangles and plaque amyloid
increase in amounts in the ageing brain without causing neuronal
death or cognitive impairment. If, however, there is concurrent
proteasomal malfunction or impairment in the same brains, further
pathologywill occur with Lewy body formation, followed by extensive
neuronal death and irreversible cognitive decline and ﬂorid dement-
ing illness. This “UPS critical failure” model could explain the
transition from normal aging to disease. Whether 26S proteasomal
dysfunction always occurs in human chronic neurodegenerative
disease is not proven: that 26S proteasomal depletion causes
neurodegeneration in the mouse is proven [81].
It is not yet clear what the exact role of the neuronal Lewy body is
in this situation. Opinion on the role of the Lewy body swings like a
pendulum from protector to villain. The current position of the
pendulum favours a cytoprotective role, particularly if the Lewy body
is seen as an “aggresome” [90]. There are only three known
mechanisms for the disposal of problem proteins in the cell:
degradation by the UPS, degradation by autophagy or incorporation
into aggresomes [10]. Degradation by the endosome-lysosome system
is also available for proteins internalized from the cell surface [91]. It
is now clear from gene targeting studies that ablation of autophagy
genes in the brain, while leading to neurodegeneration with
accumulation of ubiquitylated proteins, does not cause features ofhway is triggered by neuronal protein aggregation and activation of cell survival genes
. Eventual 26S proteasomal failure is caused by protein oligomers that trigger neuronal
me-dependent cell death.
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proteasomal Psmc1 ATPase does recapitulate human neuropathology
including Lewy-like bodies. In the 26S proteasome-deﬁcient neurons
proteins accumulate in perinuclear structures most likely built around
the microtubule organizing centre (centrosome) like in EBV-virus
transformed cells [86]. These structures are very similar to the
aggresomes seen in different experimental models with aggregate-
prone proteins. For operational purposes the Lewy body is almost
certainly derived from a neuronal aggresome. Experimental aggre-
somes contain vimentin ﬁlaments and components of the UPS as well
as peripheral autophagolysosomes presumably trying to degrade the
aggresomal proteins [92]. When the UPS was in its infancy, protein
microinjection studies into several tissue culture cell types showed
that injected proteins were transported to a perinuclear “protein
sequestration site associated with the microtubule organizing centre
for protein degradation by autophagy” [93,94], like in EBV-trans-
formed lymphoblastoid cells [86]. Protein overload, whether in the
cytosol or plasma membrane, sent proteins to this site quickly
followed by slow autophagolysosomal degradation of the proteins
(24–96 h). In the substantia nigra, ablation of the expression of the
proteasomal Psmc1 gene results in relatively rapid Lewy body
formation (within 2 weeks).
In the 26S proteasome deﬁcient models, electron microscopy
shows that Lewy-like bodies are ﬁlled with mitochondria. In the EBV-
transformed cells mitochondria were also a prominent feature of the
inclusions [86]. There have been few reports of mitochondria in Lewy
bodies [87,95], but the mitochondrial inner-membrane PINK kinase is
found experimentally in Lewy bodies [96]. The PINK kinase is mutated
in familial Parkinson's disease and appears to act in mitochondria
upstream of mitochondrial parkin [97,98]. The PINK kinase and parkin
seem to control mitochondrial ﬁssion [99]. The proportion of neuronal
mitochondria that are incorporated into Lewy bodies is unknown.
However, mitochondria have a central role in chronic neurodegen-
erative diseases, most strikingly in Parkinson's disease [96]. If Lewy
bodies prolong the life of the neuron then could the ability to form
Lewy bodies be dependent on normal mitochondria? Lewy bodies
generally do not form in Parkinson's disease associated with parkin
mutations [100]. Mitochondria are integral to the intrinsic pathway of
apoptosis by releasing cytochrome c, triggering apoptosome forma-
tion and the activation of caspases 9 and 3 [101]. It is tempting to
speculate that if mitochondria in early forms (pale bodies) of Lewy
bodies [102] (whichmay be in the early inclusions to provide localized
ATP for the biogenesis of early forms of Lewy bodies) are not
subsequently removed these mitochondria may act as apoptotic
“detonators” which trigger apoptosis by mechanisms including the
localized release of cytochrome c. Surviving neurons, in which
mitochondria are removed from maturing inclusions, will escape
such a process and display the mature Lewy bodies.
5. A unifying intraneuronal mechanism involving 26S proteasome
malfunction and cell death in neurodegeneration
Critical failure of the 26S proteasome may be at the heart of an
escalating process of neurodegeneration, in which adverse stimuli
combine to increase the magnitude of regional neurodegeneration in
the brain. Upstream events involving parkin andα-synucleinmay also
be major players in the disease process (Fig. 2).
This process would be initiated by the accumulation of different
types of intraneuronal proteins, triggering chaperone, UPS, autophagic
and cell survival responses followed by inclusion body biogenesis. As a
consequence of 26S proteasome inhibition by aggregate-prone
proteins [56,103,104], or as shown genetically in the mouse models,
26S proteasome malfunction or depletion triggers neuronal death,
which, because of the interacting neuronal pathways and projections,
escalates to result in the extensive regional neurodegeneration
characteristic of human disease.Clearly, the 26S proteasome is central for neuronal survival and
depletion of 26S proteasomes by ablation of the Psmc1 ATPase in
appropriate speciﬁc regions of the brain recapitulates neuropatholo-
gical and behavioral features of two major human chronic neurode-
generative diseases.
6. What now in 26S proteasome-depleted animals?
There are several predictions and hypotheses that can now be
made as a result of the generation of the Lewy mouse and ensuing
recapitulation of the pathology of human neurodegenerative disease
including;
• The α-synuclein protein is necessary for the Lewy-like response in
neurons
• Early involvement of mitochondria is a key feature of the Lewy
body response and
• Failure to abrogate the causative stimulus for Lewy body formation
leads to mitochondrial-dependent apoptosis: this is a critical factor
during Lewy body biogenesis and equates with the “pale body”
seen in human disease
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